Mendoza becomes the first Argentine province to screen newborns for spinal muscular atrophy at birth, enabling pre-symptomatic treatment under a public-private accord with Novartis effective May 24, 2026.

PHARMA · NEUROSCIENCE · MAY 24, 2026 · LATIN AMERICA
A provincial health decision made in Mendoza on May 24, 2026 carries implications that extend well beyond its borders. Under a public-private accord between the Mendoza government and Novartis, spinal muscular atrophy — a progressive and frequently fatal genetic disease — has been added to the province’s routine newborn heel-prick screening panel, according to reporting by Infobae. Mendoza is the first Argentine province to take this step, establishing a model that other jurisdictions will now be under pressure to evaluate.
System Implications
Spinal muscular atrophy is caused by mutations in the SMN1 gene and, in its most severe forms, leads to irreversible motor neuron loss within the first months of life. The clinical rationale for neonatal screening rests on a well-established principle: therapeutic intervention before symptom onset is associated with substantially better motor outcomes than treatment initiated after neurological damage has begun. The Mendoza accord operationalizes that principle at the population level for the first time in Argentina.
By integrating SMA detection into the existing heel-prick infrastructure — a screening mechanism already in place for metabolic and other genetic conditions — the province avoids building a parallel diagnostic pathway. This suggests the marginal operational cost of adding SMA to the panel may be lower than establishing a standalone program, though no specific cost data has been published to confirm this assessment.
The public-private structure of the accord is notable. Novartis’s participation formalizes a role for the manufacturer of Zolgensma — the one-time gene therapy indicated for SMA — in the architecture of early detection. Further data is needed to assess the precise scope of Novartis’s operational and financial contribution under the agreement.
Patient Access
For affected newborns, the screening change compresses the diagnostic timeline from what has historically been a months-long process of symptom recognition and specialist referral to a window measurable in days after birth. According to the Infobae report, the program is designed to enable pre-symptomatic treatment — meaning intervention before motor loss becomes clinically apparent.
Two therapies are positioned within this early-intervention window: Zolgensma, Novartis’s gene therapy administered as a single intravenous infusion, and nusinersen, marketed as Spinraza, an intrathecal antisense oligonucleotide requiring repeated dosing. Both are indicated for SMA, though their eligibility criteria, dosing logistics, and cost profiles differ substantially. Provincial announcements do not specify which therapy or therapies the program will prioritize, nor do they confirm reimbursement arrangements for either product under the accord.
Access to either treatment at the provincial level in Argentina involves coverage determinations that extend beyond the screening program itself. The existence of a confirmed diagnosis does not automatically resolve the reimbursement pathway — a distinction that will matter for families and clinicians navigating the system after a positive screen.
Industry and Payer Implications
For Novartis, the Mendoza accord represents more than a single-province commercial opportunity. A confirmed SMA diagnosis in a pre-symptomatic newborn creates a defined, time-sensitive clinical decision point — precisely the conditions under which gene therapy is most clinically defensible and, for the manufacturer, most commercially relevant. The earlier the diagnosis, the stronger the clinical case for Zolgensma relative to chronic maintenance therapy.
Payers operating in Mendoza — including obras sociales and prepaid health plans — will need to establish or clarify coverage protocols for SMA treatment triggered by neonatal screening results. The screening program creates a new category of confirmed-but-asymptomatic patients who will require coverage decisions before clinical deterioration occurs. Organizations without an existing SMA treatment pathway will need to develop one, and the May 24 effective date means that process should already be underway.
Provincial health ministries in other Argentine jurisdictions face a related operational question: whether to replicate the Mendoza model and, if so, whether to negotiate similar public-private structures or pursue purely public procurement. The Mendoza accord, described by Infobae as a national precedent, may accelerate that evaluation cycle.
Regulatory and Legal Considerations
The accord between the Mendoza government and Novartis is described as confirmed and effective as of May 24, 2026, per the Infobae report. No pending regulatory review, legal challenge, or unresolved approval process has been reported in connection with the screening program itself. SMA screening at the neonatal level does not appear to require new federal regulatory authorization beyond existing provincial health authority, though the regulatory basis for the provincial decision has not been explicitly stated.
Any subsequent coverage or reimbursement decisions for Zolgensma or nusinersen triggered by screening results would be subject to existing Argentine coverage frameworks, which provincial announcements do not detail. Those determinations remain outside the scope of the screening accord as described.
Counterpoint
The principal counterargument is that a confirmed screening program does not resolve the most consequential bottleneck in SMA care: treatment access. Zolgensma carries one of the highest list prices of any pharmaceutical product globally, and Argentina’s fragmented payer landscape — spanning provincial public systems, national obras sociales, and private prepaid plans — has no uniform mechanism for absorbing that cost. A positive neonatal screen that cannot be followed by timely, funded treatment does not deliver the clinical benefit the program promises. The risk is that the screening infrastructure outpaces the reimbursement infrastructure, creating a diagnostic pipeline that identifies patients earlier but does not reliably connect them to therapy. If that gap persists, the public health value of the program will be substantially diminished regardless of the screening protocol’s technical quality.
Strategic Outlook
The Mendoza model introduces a replicable template for incorporating rare genetic diseases into existing neonatal screening infrastructure through public-private agreements. One possible scenario is that other Argentine provinces use the Mendoza accord as a negotiating reference point — either to replicate the Novartis partnership structure or to use it as leverage in procurement discussions with competing manufacturers. Whether the model expands will depend in part on how clearly the Mendoza program can demonstrate operational feasibility and, eventually, clinical outcomes in the screened cohort.
For Novartis, the strategic value of the accord is partly diagnostic-funnel construction: a province that screens for SMA at birth generates a defined population of confirmed cases at the moment of maximum therapeutic opportunity. If the model extends to additional provinces, that funnel scales accordingly. No formal expansion discussions have been confirmed, and replication should be treated as a possibility rather than a planned outcome.
What to Watch
- Whether Argentine federal health authorities move to incorporate SMA into the national mandatory neonatal screening panel, which would supersede provincial-level variation.
- Coverage and reimbursement decisions by major obras sociales and provincial health ministries for SMA therapies triggered by neonatal screening — the operational gap most likely to determine program impact.
- Whether other Argentine provinces announce similar public-private screening accords, and whether Novartis or competing manufacturers participate in those structures.
Closing Insight
The Mendoza accord effectively transfers a portion of the market-shaping function — defining who gets diagnosed, when, and through what institutional channel — from the clinical referral system to a public health infrastructure co-designed with the manufacturer whose product benefits most from early diagnosis. That structural alignment between screening architecture and commercial interest is worth monitoring as the model is evaluated for replication.
Intelligence Briefing
SMA Newborn Screening — Mendoza & the Global Treatment Landscape
Advisory Committee on Heritable Disorders recommends SMA added to the U.S. Recommended Uniform Screening Panel, enabling pre-symptomatic treatment access nationwide.
FDA clears onasemnogene abeparvovec-brve (Itvisma) for SMA patients aged 2 and older — expanding gene therapy access beyond infants for the first time. SMA affects approximately 4–10 per 10,000 live births. (Source: FDA, Nov 2025)
Mendoza becomes Argentina’s first province to include SMA in mandatory newborn screening. A public-private accord with Novartis enables pre-symptomatic identification — opening the intervention window before irreversible motor neuron loss.
Mendoza’s model — combining universal screening with a structured pharma partnership — positions it as a replicable blueprint for other Argentine provinces and LATAM markets seeking to close the pre-symptomatic treatment gap for rare genetic diseases.
Sources: FDA Press Release Nov 24 2025 · FDA Summary Basis for Regulatory Action BLA 125856/0 · HealthSignals LATAM Intelligence
Related coverage
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.







